EP0820302A1 - Combination compositions containing benazepril or benazeprilat and valsartan - Google Patents

Combination compositions containing benazepril or benazeprilat and valsartan

Info

Publication number
EP0820302A1
EP0820302A1 EP96910948A EP96910948A EP0820302A1 EP 0820302 A1 EP0820302 A1 EP 0820302A1 EP 96910948 A EP96910948 A EP 96910948A EP 96910948 A EP96910948 A EP 96910948A EP 0820302 A1 EP0820302 A1 EP 0820302A1
Authority
EP
European Patent Office
Prior art keywords
active ingredient
composition according
ingredient component
valsartan
benazepril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96910948A
Other languages
German (de)
English (en)
French (fr)
Inventor
Marc De Gasparo
Randy Lee Webb
David Saul Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG filed Critical Ciba Geigy AG
Publication of EP0820302A1 publication Critical patent/EP0820302A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
EP96910948A 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan Withdrawn EP0820302A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1012/95 1995-04-07
CH101295 1995-04-07
PCT/EP1996/001440 WO1996031234A1 (en) 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan

Publications (1)

Publication Number Publication Date
EP0820302A1 true EP0820302A1 (en) 1998-01-28

Family

ID=4200393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96910948A Withdrawn EP0820302A1 (en) 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan

Country Status (15)

Country Link
EP (1) EP0820302A1 (hu)
JP (1) JPH11503139A (hu)
KR (1) KR19980703647A (hu)
CN (1) CN1181019A (hu)
AU (1) AU5399096A (hu)
BR (1) BR9604818A (hu)
CA (1) CA2214143A1 (hu)
CZ (1) CZ313897A3 (hu)
HU (1) HUP9801593A2 (hu)
MX (1) MX9707683A (hu)
NO (1) NO974400D0 (hu)
PL (1) PL322529A1 (hu)
SK (1) SK133897A3 (hu)
TR (1) TR199701121T1 (hu)
WO (1) WO1996031234A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508894A (ja) * 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
AR032152A1 (es) * 2000-04-12 2003-10-29 Novartis Ag Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica
CA2415962C (en) * 2000-07-19 2010-07-06 Novartis Ag Valsartan salts
EP1671632A1 (en) * 2000-08-22 2006-06-21 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
WO2002049645A1 (en) * 2000-12-18 2002-06-27 Novartis Ag Therapeutic combination of amlodipine and benazepril
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
CN100377744C (zh) * 2002-07-05 2008-04-02 安徽省生物医学研究所 一种预测acei类降压药药效的复方药
WO2004019876A2 (en) * 2002-08-28 2004-03-11 Curis, Inc. Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
JP5612674B2 (ja) 2009-05-20 2014-10-22 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミットベシュレンクテル ハフツング テルミサルタンを含む経口懸濁液
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
MX2016010011A (es) * 2014-01-31 2016-10-07 Janssen Pharmaceutica Nv Metodos para tratar y prevenir trastornos renales y trastornos del higado graso.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148632T1 (de) * 1990-05-11 1997-02-15 Pfizer Synergistische therapeutische zusammensetzungen und verfahren
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9631234A1 *

Also Published As

Publication number Publication date
AU5399096A (en) 1996-10-23
BR9604818A (pt) 1998-06-09
MX9707683A (es) 1997-12-31
CZ313897A3 (cs) 1998-01-14
NO974400L (no) 1997-09-23
PL322529A1 (en) 1998-02-02
WO1996031234A1 (en) 1996-10-10
CA2214143A1 (en) 1996-10-10
JPH11503139A (ja) 1999-03-23
HUP9801593A2 (hu) 1999-01-28
CN1181019A (zh) 1998-05-06
KR19980703647A (ko) 1998-12-05
TR199701121T1 (xx) 1998-03-21
NO974400D0 (no) 1997-09-23
SK133897A3 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
EP2322174B1 (en) Combined use of valsartan and calcium channel blockers for therapeutic purposes
RU2316318C2 (ru) Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
CN102091330B (zh) 含有缬沙坦和nep抑制剂的药物组合物
US8404744B2 (en) Methods of treatment and pharmaceutical composition
WO1996031234A1 (en) Combination compositions containing benazepril or benazeprilat and valsartan
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
US20010049384A1 (en) Method of treatment and pharmaceutical composition
EP0641218B1 (en) Use of angiotensin antagonist (at1) for reducing post myocardial infarct mobidity and mortality
JP2003533440A (ja) 隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤
Su et al. Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure: Differential acute effects according to the renin-angiotensin system activation
CN106267147A (zh) 一种复方降压药物组合物
KR20230006884A (ko) 뇌 아미노펩티다제 a 억제제, 이뇨제, 및 전신 레닌-안지오텐신 시스템의 차단제를 포함하는 약학 병용물
Waeber et al. Antihypertensive Agents: Mechanisms of Drug Action
WO2003007964A1 (fr) Remede ou agent preventif de cardiopathie ou d'anevrysme contenant un compose d'inhibition de la chymase
Adam et al. O-33: Omapatrilat (OMA) a vasopeptidase inhibitor prevents mortality and cardiovascular injury in salt sensitive hypertension in addition to but independent of blood pressure
Lisy et al. O-35: Blood pressure lowering, renin suppressing and natriuretic properties of a new designer peptide BD-NP
Muntinghe et al. Sodium status and the response to blockade of the renin-angiotensin system
WO2017072636A1 (en) Pharmaceutical synergistic combination
WO2005039638A2 (en) Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor
AU2006202999A1 (en) Pharmaceutical compositions comprising valsartan and NEP inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970825

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991103